Association Between Fatigue, Information Processing Speed and Plasma Levels of Glial Fibrillary Acidic Protein and Neurofilament Light in Patients With Relapsing–Remitting Multiple Sclerosis Treated With Natalizumab or Rituximab.
Saved in:
| Title: | Association Between Fatigue, Information Processing Speed and Plasma Levels of Glial Fibrillary Acidic Protein and Neurofilament Light in Patients With Relapsing–Remitting Multiple Sclerosis Treated With Natalizumab or Rituximab. |
|---|---|
| Authors: | Hellgren, Johan (AUTHOR), Compagno Strandberg, Maria (AUTHOR), Hansson, Oskar (AUTHOR), Janelidze, Shorena (AUTHOR), Källén, Kristina (AUTHOR), Svenningsson, Anders (AUTHOR), Fee, Dominic B. (AUTHOR) |
| Source: | Acta Neurologica Scandinavica. 4/29/2026, Vol. 2026, p1-8. 8p. |
| Subjects: | Fatigue (Physiology), Glial fibrillary acidic protein, Natalizumab, Multiple sclerosis, Cognitive processing speed, Biomarkers, Rituximab |
| Abstract: | Background: Patients with relapsing–remitting multiple sclerosis (RRMS) experience fatigue and impaired information processing speed (IPS) frequently, even in the absence of clinical or radiological disease activity. Previous studies investigating associations between fatigue, IPS, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have reported conflicting results. Objective: To examine potential associations between GFAP and NfL with fatigue and IPS in patients with RRMS treated with rituximab (RTX) or natalizumab (NTZ). Methods: In this Swedish multicentre cross‐sectional study, we measured plasma GFAP and NfL levels using Simoa Neurology 2‐PLEX B Kit in 121 clinically stable patients with RRMS treated with either RTX or NTZ for at least 24 months. Fatigue and IPS were assessed using the Fatigue Scale for Motor and Cognitive Functions (FSMC) and the Symbol Digit Modalities Test (SDMT), respectively. Results: No significant associations were found between GFAP or NfL levels and FSMC or SDMT scores. No significant differences in GFAP or NfL levels were observed between RTX‐ and NTZ‐treated groups. Conclusion: No associations were found between fatigue, IPS, GFAP and NfL. GFAP and NfL levels in stable RRMS patients treated with off‐label RTX were low and did not significantly differ from those treated with NTZ, possibly suggesting a low risk of long‐term disability progression for patients treated with either therapy. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Patients with relapsing–remitting multiple sclerosis (RRMS) experience fatigue and impaired information processing speed (IPS) frequently, even in the absence of clinical or radiological disease activity. Previous studies investigating associations between fatigue, IPS, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have reported conflicting results. Objective: To examine potential associations between GFAP and NfL with fatigue and IPS in patients with RRMS treated with rituximab (RTX) or natalizumab (NTZ). Methods: In this Swedish multicentre cross‐sectional study, we measured plasma GFAP and NfL levels using Simoa Neurology 2‐PLEX B Kit in 121 clinically stable patients with RRMS treated with either RTX or NTZ for at least 24 months. Fatigue and IPS were assessed using the Fatigue Scale for Motor and Cognitive Functions (FSMC) and the Symbol Digit Modalities Test (SDMT), respectively. Results: No significant associations were found between GFAP or NfL levels and FSMC or SDMT scores. No significant differences in GFAP or NfL levels were observed between RTX‐ and NTZ‐treated groups. Conclusion: No associations were found between fatigue, IPS, GFAP and NfL. GFAP and NfL levels in stable RRMS patients treated with off‐label RTX were low and did not significantly differ from those treated with NTZ, possibly suggesting a low risk of long‐term disability progression for patients treated with either therapy. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00016314 |
| DOI: | 10.1155/ane/5453262 |
